Mendus AB (“Mendus” publ; IMMU.ST) will publish its financial report for the second quarter 2026 on Thursday, August 20, at 08.00 CEST. The company will host a live presentation and business update on the same day at 14.00 CEST. The presentation will be held in English and includes a Q&A session.
Date and time: August 20 at 14.00 CEST
If you wish to participate via webcast please register using the link below. Via the webcast you are able to ask written questions.
https://portals.qbrick.com/520c8ac4
If you wish to participate via teleconference please register using the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.
https://event-registration.qbrick.com/AccDlMhN1SbO0mSeNwyp64iGw/019ff551-6595-7984-861c-72e68843e0a9/qbrick-meet-e6b334ca-c4ba-4f2b-bf86-7e8b69bd623b
For more information, please contact:
Erik Manting
Chief Executive Officer
E-mail: ir@mendus.com
About Mendus AB (publ)
Mendus is a clinical-stage biopharmaceutical company dedicated to transforming immunotherapy for myeloid malignancies. Based in Sweden and the Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST.
https://www.mendus.com/